Just getting acquainted with decentralized science (DeSci)? Let me share how DeSci and BioDAOs operate from my talk last week at @EFDevcon in Bangkok.
DeSci 2049 is a vision for the future of science that combines biotechnology with a permissionless market driven by open scientific data and free markets.
Many people invest in cryptocurrencies to maintain our autonomy and the freedoms that are gradually being stripped away.
A similar movement is also forming in the fields of science and medicine, as our freedom for innovation, self-experimentation, and scientific dissemination is being eroded by an imperfect biomedical R&D system.
The current system does not encourage curing diseases. Goldman Sachs downgraded its rating in 2018 for a biopharmaceutical company that created a cure for hepatitis C, questioning whether curing patients is a 'sustainable business model.'
Scientists spend too much time seeking funding instead of focusing on scientific research. Imagine if software developers spent most of their time raising funds instead of writing code.
Many scientific talents around the world remain underutilized.
We have failed to realize a vision for a rich solarpunk future because we have not upgraded the foundations of science and technology.
What if we could build a permissionless scientific world?
A self-sovereign science defined by an open data and fluid market designed to find cures.
So what is the role of @Molecule_dao and @bioprotocol in this?


Molecule is a protocol that puts scientific intellectual property on-chain.


BIO is a launch and acceleration engine designed for on-chain scientific communities (BioDAOs), bringing together scientists, patients, and investors.


BioDAOs are dedicated to developing intellectual property on-chain (including research, drugs, and products), focusing on specific scientific fields or diseases.
For example, @vita_dao has funded multiple longevity science and research projects, including the VITA-FAST project at @UniofNewcastle led by @Vikorolchuk's lab.
Our team has assisted in establishing the first BioDAOs across multiple scientific fields.
Last week when I spoke, the total market capitalization of BioDAOs in our network was less than $100 million, and it has now exceeded $230 million!
BIO guides scientists, patients, and biotechnology founders to transition the scientific community on-chain, from token economics and community building to funding and liquidity management.
BIO holders vote to incorporate DAOs into the network, similar to a community-owned accelerator that enables exceptional teams to stand out and launch their communities on-chain.
Projects set to launch on the BIO platform include @endrarediseases, @QuantumBioDAO, and @longcovidlabs.
Some new BioDAOs focus on specific patient populations seeking solutions for their conditions and accelerating new pathways for treatment.
To kick off this protocol, BIO recently held a Genesis event, inviting users to deposit supported DeSci tokens in exchange for BIO tokens. The Genesis event raised $33 million for the BIO treasury, and due to the increase in the price of DeSci tokens, the treasury now exceeds $53 million. The treasury can be tracked here.
In addition, @BinanceLabs has also invested in $BIO.
Overall, BIO sits at the top of the BioDAOs network, with each BioDAO developing specific drugs and therapeutic solutions as tokenized scientific intellectual property.
Every stage of drug development has historically been opaque to the public. BioDAOs aim to advance every stage of drug development in a more open and transparent manner through blockchain technology.
At the core of this new model are IP-NFTs, which allow anyone to anchor intellectual property on-chain, granting it programmability, tradability, liquidity, and rich data.
Essentially, IP-NFTs are containers for intellectual property.
Once intellectual property is fully validated, IP-NFTs can be split into IPTs, serving as governance tokens that allow individuals to actively participate in the scientific process.
IP-Tokens are the core building blocks driving shared ownership of intellectual property in the DeSci economy.
VITARNA Case Study:
With the support of @vita_dao, Vita-RNA is developing a new type of mRNA gene therapy, led by experienced biotech founders @Mykalt45 and @aschwartzphd.
Received $300,000 in support; now has a market cap of $27 million.
One of Vita-RNA's major drug candidates has shown activity in vitro, driving the price of its token up on Uniswap.
So, what’s the next step for the BIO Protocol? Please note that all dates are subject to change.
We are inspired by the growing bio/acc movement.
The goal of bio/acc is to accelerate the advancement of biology and challenge many of the conventional notions about health and medicine that we have been taught since childhood.
We have been taught from a young age to accept aging as a fact.
This fund transformation is a mistake.
We must rely on companies and institutions to drive scientific advancement.
The pharmaceutical industry can save lives.
If computation is the foundation of intelligence, then biotechnology is the foundation of life.
This is a call to accelerate the development of biotechnology.
Biotechnology acceleration: accelerating longevity, neuroscience, genetic engineering, synthetic biology, fertility, and life bio/acc.
Please sign the bio/acc declaration at bioacc.life.
We must radically reform outdated scientific institutions and processes to accelerate biomedical discoveries.
And establish a global scientific network that allows anyone to participate.